INS and type 1 diabetes mellitus: The IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT) trial (clinicaltrials.gov/NCT04524949) will test a proinsulin-derived mimotope in patients with diabetes and use AIM and RNA-Seq to characterize the subsequent immune signature to identify treatment-specific biomarkers.